Literature DB >> 18801660

New acridone-4-carboxylic acid derivatives as potential inhibitors of hepatitis C virus infection.

Anna Stankiewicz-Drogon1, Larisa G Palchykovska, Valentina G Kostina, Inna V Alexeeva, Anatoly D Shved, Anna M Boguszewska-Chachulska.   

Abstract

A new class of compounds--acridone derivatives--was tested using the direct fluorometric helicase activity assay to determine the inhibitory properties of the derivatives towards the NS3 helicase of Hepatitis C virus (HCV). The compounds were also tested as putative transcription inhibitors of in vitro transcription based on the DNA-dependent T7 RNA polymerase. Most of the acridone derivatives tested were transcription inhibitors; however, only four of them inhibited the NS3 helicase at low concentrations (IC(50) from 3 microM to 20 microM) and were therefore selected for further studies on the mechanism of inhibition. The acridone derivatives probably act via intercalation into double-stranded nucleic acids but they may also interact directly with viral enzymes. Selected carboxamides were tested in the subgenomic HCV replicon system. Two of the compounds: N-(pyridin-4-yl)-amide and N-(pyridin-2-yl)-amide of acridone-4-carboxylic acid are efficient RNA replication inhibitors with selectivity indexes of 19.4 and 40.5, respectively, proving that the acridone derivatives may be regarded as potential antiviral agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18801660     DOI: 10.1016/j.bmc.2008.08.074

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  9 in total

1.  Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline.

Authors:  Kelin Li; Kevin J Frankowski; Craig A Belon; Ben Neuenswander; Jean Ndjomou; Alicia M Hanson; Matthew A Shanahan; Frank J Schoenen; Brian S J Blagg; Jeffrey Aubé; David N Frick
Journal:  J Med Chem       Date:  2012-03-22       Impact factor: 7.446

2.  Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C.

Authors:  Craig A Belon; David N Frick
Journal:  Future Virol       Date:  2009-05-01       Impact factor: 1.831

3.  UK-1 and structural analogs are potent inhibitors of hepatitis C virus replication.

Authors:  Dawn N Ward; Daniel C Talley; Mrinalini Tavag; Samrawit Menji; Paul Schaughency; Andrea Baier; Paul J Smith
Journal:  Bioorg Med Chem Lett       Date:  2013-12-09       Impact factor: 2.823

Review 4.  Development of novel antiviral therapies for hepatitis C virus.

Authors:  Kai Lin
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

5.  Antiviral drugs against hepatitis C virus.

Authors:  Sidra Rehman; Usman A Ashfaq; Tariq Javed
Journal:  Genet Vaccines Ther       Date:  2011-06-23

6.  Antiviral activity of an N-allyl acridone against dengue virus.

Authors:  María B Mazzucco; Laura B Talarico; Sezen Vatansever; Ana C Carro; Mirta L Fascio; Norma B D'Accorso; Cybele C García; Elsa B Damonte
Journal:  J Biomed Sci       Date:  2015-04-17       Impact factor: 8.410

Review 7.  Antivirals against Chikungunya Virus: Is the Solution in Nature?

Authors:  Daniel Oliveira Silva Martins; Igor de Andrade Santos; Débora Moraes de Oliveira; Victória Riquena Grosche; Ana Carolina Gomes Jardim
Journal:  Viruses       Date:  2020-02-29       Impact factor: 5.048

Review 8.  Hepatitis C virus NS3 inhibitors: current and future perspectives.

Authors:  Kazi Abdus Salam; Nobuyoshi Akimitsu
Journal:  Biomed Res Int       Date:  2013-10-27       Impact factor: 3.411

Review 9.  Inhibition of RNA Helicases of ssRNA(+) Virus Belonging to Flaviviridae, Coronaviridae and Picornaviridae Families.

Authors:  Irene Briguglio; Sandra Piras; Paola Corona; Antonio Carta
Journal:  Int J Med Chem       Date:  2010-11-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.